Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Anti-ROR1 antibody and ROR1-targeting engineered cells
US12492264B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12492264-B2 |
| Application number | US-202418430202-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 1, 2024 |
| Priority date | May 24, 2022 |
| Publication date | Dec 9, 2025 |
| Grant date | Dec 9, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating a ROR1-positive tumor comprising administering to a patient having a tumor a therapeutic composition comprising an immune cell comprising an anti-ROR1 chimeric antigen receptor (CAR), wherein the CAR comprises a single-chain variable fragment (scFv) having a heavy chain variable region (V H ) and a light chain variable region (V L ), and the V H comprises SEQ ID NO: 17, and the V L comprises SEQ ID NO: 18. 2 . The method of claim 1 , wherein the scFv comprises SEQ ID NO: 16. 3 . The method of claim 2 , wherein the scFv consists of SEQ ID NO: 16. 4 . The method of claim 1 , wherein the CAR comprises the amino acid sequence of SEQ ID NO: 19 without the signaling peptide consisting of SEQ ID NO: 22. 5 . The method of claim 4 , wherein the CAR consists of the amino acid sequence of SEQ ID NO: 19 without the signaling peptide consisting of SEQ ID NO: 22. 6 . The method of claim 5 , wherein the CAR is encoded by a nucleic acid comprising SEQ ID NO: 39. 7 . The method of claim 1 , wherein the cell is selected from a CAR-T cell and a CAR-NK (natural killer) cell. 8 . The method of claim 1 , wherein the cell is allogeneic. 9 . The method of claim 1 , wherein the composition further comprises an excipient.
Assignees
Inventors
Classifications
Vectors comprising a coding region that has been codon optimised for expression in a respective host · CPC title
viral genome or elements thereof as genetic vector · CPC title
viral genome or elements thereof as genetic vector · CPC title
Viral vectors · CPC title
T lymphocytes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12492264B2 cover?
- The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimul…
- Who is the assignee on this patent?
- Caribou Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).